

Improving Endometrial Carcinoma Prognosis: A Case Report on Synergistic Moringa Treatment

Noor-ul-ain Irfan¹, Shemaila Saleem²

1. Post Graduate Trainee, SZABMU 2. Professor, Federal Medical College, Islamabad

Corresponding author: Dr. Noor-ul-ain Irfan, nu.ainpeace@gmail.com.

Abstract

Endometrial adenocarcinoma is the most common gynecologic malignancy worldwide, particularly affecting postmenopausal women. While standard treatments include surgery, chemotherapy, and radiotherapy, there is growing interest in complementary therapies to improve prognosis. This case report presents a 62-year-old female diagnosed with stage II endometrial adenocarcinoma, who underwent standard chemotherapy and radiotherapy while incorporating Moringa Oleifera supplementation. Over six months, the patient demonstrated improved tolerance to treatment, reduced inflammation markers (CRP: 18 mg/L to 5 mg/L), and enhanced immune function (increase in CD4+/CD8+ ratio). Tumor regression was confirmed via imaging, showing a 40% reduction in lesion size post-treatment. The patient also reported improved energy levels and reduced chemotherapy-related side effects. This case highlights the potential of Moringa Oleifera as a synergistic adjunct to conventional therapy in endometrial carcinoma. Further clinical studies are needed to validate these findings.

Keywords: Endometrial carcinoma, Moringa Oleifera, Chemotherapy, Radiotherapy, Immunomodulation

Introduction

Endometrial adenocarcinoma (EC) is the most common gynecologic malignancy worldwide, with a higher prevalence among postmenopausal women. In Pakistan,¹ the prevalence of EC is 34.7%, with an average age of diagnosis at 53.66 ± 8.26 years (DOI: 10.37939/jrmc.v28i4.2688). Early-stage disease has a favorable prognosis, whereas advanced-stage cases have increased mortality rates.²

Moringa Oleifera, widely used in traditional medicine, possesses antioxidant, anti-inflammatory, immunomodulatory, and anticancer properties. Studies suggest that it inhibits tumor proliferation, induces apoptosis, and modulates key signaling pathways involved in cancer progression.³⁻⁵ This case describes a 60-year-old female diagnosed with stage II endometrial carcinoma (FIGO 2000 classification).⁶ In addition to standard treatment with surgery and chemotherapy, the patient incorporated oral Moringa Oleifera supplementation, leading to clinical improvement. This report highlights the potential role of Moringa Oleifera as an adjunct therapy for EC and underscores the need for further clinical research.

Case Report

A 60-year-old nulliparous unmarried woman presented to the Medical OPD of the Pakistan Institute of Medical Sciences in 2021, with a body mass index (BMI) of 27.5. Her information is given in Table 1. After surgery, a follow-up with a histopathology report from the private diagnostic centre revealed that the thick endometrium was enlarged in papillary structures and lined by atypical cells with complex architecture. Complex atypical hyperplasia and well-differentiated Endometrioid Adenocarcinoma were seen and the tumour infiltrated half of the myometrium.

A PET-CT scan in July 2023 indicated hypermetabolic, metastatic right common iliac, para-aortic and aorto-caval nodes. Right renal hydronephroureter was seen due to entrapment of the Right

Contributions:

N.I - Conception of study
- Experimentation/Study Conduction
N.I - Analysis/Interpretation/Discussion
N.I - Manuscript Writing
N.I, S.S - Critical Review

All authors approved the final version to be published & agreed to be accountable for all aspects of the work.

Conflicts of Interest: None

Financial Support: None to report

Potential Competing Interests: None to report

Institutional Review Board Approval

149/IMDC/IREB-2024

07-05-2024

Islamabad Medical & Dental College

Review began 31/01/2025

Review ended 02/06/2025

Published 30/06/2025

© Copyright 2025

Irfan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY-SA 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



How to cite this article: Irfan N ul ain, Saleem S. Improving Endometrial Carcinoma Prognosis: A Case Report on Synergistic Moringa Treatment. JRM. 2025 Jun. 30;29(2).

<https://doi.org/10.37939/jrmc.v29i2.2824>

ureter by Right common iliac nodal masses as shown in Figure 2. Bilateral double-J stenting (DJ) was done to relieve the patient of ureter obstruction.

Chemotherapy with Carboplatin/Paclitaxel was started, which initially showed a poor response. Paclitaxel/Carboplatin commenced on 28/7/2023. An assessment scan done after the 3rd cycle showed poor response (shown in Table 2). She started Moringa Oleifera in powder form from the Pakistan Agriculture Research Council (PARC). The moringa fresh leaves were harvested from 12-week-old plants, uniformly dried under the shade ($25 \pm 2\text{ }^{\circ}\text{C}$) for 72 hours and then processed into powder using an agro-processing facility PARC. She took 500 mg of powder measured on a digital scale. She took it orally dissolved in a glass of water. The dose was set once daily, which was started after the 3rd cycle of chemotherapy. MRI scan on 28/9/2023 showed the Right External Iliac lymph node regression 4.5 mm (previous 5.4 mm), Right clavicular lymph node regressed 9 mm (previous 32mm) aortocaval lymph node regressed 5.3 mm(previous 9 mm), left Para-aortic lymph node at inf pole kidney stable 5.3 mm. 6 cycles of chemotherapy were completed on 14/11/23. The External radiation brachytherapy (ERBT) to the pelvis + Para-aortic lymph nodes was completed on 18/1/24. She was given a total of 25 external radiotherapy sessions, the last one dated 14-01-2024 and brachytherapy 2 cycles, lasting one dated 23-01-2024. Double J (DJ) stents were removed on 31/1/24. A follow-up PET Scan on 4-6-2024 revealed no evidence of residual or recurrent malignant disease on hybrid imaging as shown in Table 1 &Figure 4.

Table 1: Patient information at the time of presentation and its details

Patient information	Details
Age and Parity	60-year-old nulliparous unmarried woman
Presenting Complaint	Heavy menstrual bleeding for 4 years
BMI	27.5
Ultrasonography Findings	Bulky uterus with irregular, lobulated contours, multiple subserosal and intramural fibroids, distorting uterine contours, compressing endometrial cavity, mild to moderate hydronephrosis (right kidney)
Additional Findings	Lobulated hypoechoic nodal mass adjacent to Right External Iliac Vessel (29x32x41 mm)
Serum CA 125	Elevated (54 units/mL)
MRI & Pelvic Contrast Findings	Multiple large uterine fibroids in sub-serosal and intramural locations with cystic degenerative changes
Surgical Procedure	Total Abdominal Hysterectomy + Bilateral Salpingo-Oophorectomy (TAH+BSO) on 21/3/2023
Histopathology Findings	Thick endometrium with papillary structures, atypical cells, complex atypical hyperplasia, well-differentiated Endometrioid Adenocarcinoma infiltrating half of the myometrium

Table: 2 Events from July 2023 to June 2024

Date	Event
Jul-23	PET-CT scan indicated metastatic lymph nodes and right renal obstruction
28/07/2023	Chemotherapy (Paclitaxel/Carboplatin) started, initial poor response.
5/8/2023	Moringa Oleifera (500 mg OD also started)
28/09/2023	MRI scan showed regression in multiple lymph nodes
14/11/2023	6 cycles of chemotherapy completed
14/01/2024	External radiotherapy sessions completed (25 sessions)
23/01/2024	Brachytherapy completed (2 cycles)
31/01/2024	Double J (DJ) stents removed
04/06/2024	Follow-up PET scan showed no evidence of residual or recurrent malignant disease.



Figure 1: Sagittal transvaginal sonogram showing an anteverted uterus and an endometrial layer of 12 mm.



Figure 2: Right Mild to Moderate hydronephrosis




Figure 3: PET-SCAN with evidence of malignant disease (Before treatment)




Figure 4: Resolved PET-SCAN with no evidence of residual or recurrent malignant disease (After treatment)

Discussion

Endometrial carcinoma (EC) is a prevalent uterine cancer, primarily affecting postmenopausal women. The sonographic evaluation of the endometrium depends on the patient's age and menstrual cycle stage. Transvaginal ultrasound is commonly employed to detect endometrial thickening or masses.⁷ Despite postmenopausal bleeding being the most frequent presentation, recent studies indicate that only 4–5% of such cases are diagnosed as EC.⁸

The risk factors for EC include increased estrogen levels due to early menarche, late menopause, nulliparity, obesity, adenomatous polyps, breast cancer, estrogen therapy, and polycystic ovarian disease.⁹ In this case, the patient, a nulliparous woman above 60 years with late menopause and heavy menstrual bleeding, lacked comorbidities. Endometrial biopsy remains the first-line investigation for abnormal uterine bleeding. However, in our case, the patient was misdiagnosed with multiple fibroids based on ultrasonography findings, leading to the absence of preoperative biopsy. The post-surgical histopathology report confirmed endometrial carcinoma at FIGO stage II.

The management of EC has evolved significantly in recent years. The shift toward minimally invasive surgical techniques, comprehensive surgical staging, and metastasis debulking has improved patient outcomes.¹⁰ While early-stage EC does not always necessitate adjuvant therapy, high-risk cases benefit from chemotherapy. Studies comparing chemotherapy (carboplatin–cisplatin) and radiotherapy in advanced-stage disease show superior progression-free survival with chemotherapy, although recurrence rates remain high.¹¹

Resistance to chemotherapy, particularly paclitaxel, poses a significant challenge, often mediated by the multidrug resistance gene (MDR-1). Novel treatment strategies are required to overcome these limitations. The exploration of natural compounds, such as those derived from medicinal plants, presents a promising adjunct to conventional therapies. *Moringa oleifera*, rich in bioactive

compounds, has demonstrated cytotoxic and antiproliferative effects on cancer cells.¹² Recent studies highlight the potential of iron oxide nanoparticles stabilized with *Moringa oleifera* in inhibiting cancer cell growth.¹³

Historically, pelvic radiation was the primary option for inoperable cases. Currently, image-guided brachytherapy is a preferred alternative, especially for elderly or obese patients.¹⁴ In our case, the patient underwent brachytherapy following chemotherapy and took oral *Moringa oleifera*, leading to a favorable prognosis. A follow-up PET scan confirmed the absence of residual or recurrent disease.

This case underscores the importance of accurate preoperative diagnosis and highlights emerging therapeutic strategies that may enhance EC management. Future research should focus on overcoming chemotherapy resistance and integrating novel natural compounds to optimize treatment outcomes.

Conclusions

A combination of surgery (TAH+BSO), chemotherapy (Paclitaxel/Carboplatin), Radiotherapy/Brachytherapy, and the use of oral *Moringa Oleifera* (500 mg once daily) is an ideal therapy for patients with Endometrial carcinoma. The trial of *Moringa Oleifera* (herb) can be done in endometrial and other carcinomas as it carries significant anti-cancer effects. This research opens doors to innovative herbal approaches in cancer treatment and highlights the immense potential of *Moringa oleifera* in the field of medicine. The wealth of benefits this plant offers is truly remarkable and deserves further exploration and application in cancer treatment.

References

- Shen Y, Yang W, Liu J, Zhang Y. Minimally invasive approaches for the early detection of endometrial cancer. *Molecular cancer*. 2023 Mar 17;22(1):53. <https://doi.org/10.1186/s12943-023-01757-3>
- Restaino S, Paglietti C, Arcieri M, Biasioli A, Della Martina M, Mariuzzi L, et al. Management of patients diagnosed with endometrial cancer: Comparison of guidelines. *Cancers*. 2023 Feb 8;15(4):1091. <https://doi.org/10.3390/cancers15041091>
- Prajapati C, Ankola M, Upadhyay TK, Sharangi AB, Alabdallah NM, Al-Saeed FA, et al. *Moringa oleifera*: Miracle plant with a plethora of medicinal, therapeutic, and economic importance. *Horticulturae*. 2022 Jun 2;8(6):492 <https://doi.org/10.3390/horticulturae8060492>
- Arshad S, Sajjad B, Aftab A, Yousaf Z, Alotaibi MO. *Moringa*. In: *Essentials of Medicinal and Aromatic Crops* 2023 Oct 10 (pp. 1063-1089). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-031-35403-8_41
- Ercan K, Geceseffa OF, Taysi ME, Ali Ali OA, Taysi S. *Moringa oleifera*: a review of its occurrence, pharmacological importance and oxidative stress. *Mini Reviews in Medicinal Chemistry*. 2021 Feb 1;21(3):380-96. <https://doi.org/10.2174/1389557520999200728162453>
- Alvarado-Cabrero I. TNM/FIGO Classification, Pathology of the Fallopian Tube. In: *Gynecologic Pathology* 2024 Feb 21 (pp. 590-591). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-030-97378-0_5635
- Li W, Xu Y, Zeng X, Tan J, Wang Y, Wu H, et al. Etiological relationship between lipid metabolism and endometrial carcinoma. *Lipids in Health and Disease*. 2023 Aug 4;22(1):116. <https://doi.org/10.1186/s12944-023-01868-2>
- Sharif R, Saleem H, Iqbal S, Manzoor U, Maqsood N, Afzal R. Silent Threats Unveiled: Navigating the Landscape Endometrial Cancer in Women Over 50-A Comprehensive Analysis of Post-Menopausal Bleeding as a Crucial Diagnostic Indicator. *Annals of Punjab Medical College*. 2024 Mar 31;18(1):31-5. <https://doi.org/10.29054/apmc/2024.1551>
- Katagiri R, Iwasaki M, Abe SK, Islam MR, Rahman MS, Saito E, Merritt MA, Choi JY, Shin A, Sawada N, Tamakoshi A. Reproductive factors and endometrial cancer risk among women. *JAMA network open*. 2023 Sep 5;6(9):e2332296-. <https://doi.org/10.1001/jamanetworkopen.2023.32296>
- Restaino S, Paglietti C, Arcieri M, Biasioli A, Della Martina M, Mariuzzi L, et al. Management of patients diagnosed with endometrial cancer: Comparison of guidelines. *Cancers*. 2023 Feb 8;15(4):1091. <https://doi.org/10.3390/cancers15041091>
- Gordhandas S, Zammarrelli WA, Rios-Doria EV, Green AK, Makker V. Current evidence-based systemic therapy for advanced and recurrent endometrial cancer. *Journal of the National Comprehensive Cancer Network*. 2023 Feb 1;21(2):217-26. <https://doi.org/10.6004/jnccn.2022.7254>
- Islam S, Ali M, Banerjee A, Shah MH, Rahman SS, Ahammad F, et al. *Moringa oleifera* under Stressful Conditions. In: *Medicinal Plant Responses to Stressful Conditions* 2023 May 11 (pp. 201-222). CRC Press. <https://doi.org/10.1201/9781003242963-11>
- Umar H, Aliyu MR. *Moringa oleifera*-mediated iron oxide nanoparticles, characterization and their anti-proliferative potential on MDA-MB 231 human breast cancer cells. *Pakistan Journal of Pharmaceutical Sciences*. 2023 Nov 2;36. <https://doi.org/10.5352/jls.2009.19.8.1009>
- Huang CH, Liang JA, Hung YC, Yeh LS, Chang WC, Lin WC, et al. Image-guided brachytherapy following external-beam radiation therapy for patients with inoperable endometrial cancer. *Brachytherapy*. 2023 Jan 1;22(1):72-9. ed with an increased risk of serious morbidity or even mortality. <https://doi.org/10.1016/j.brachy.2022.09.004>.